Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
Regístrate aquí para recibir más contenidos
Registrarse
ENDOMETRIAL
Post-Progression Survival Outcomes in Patients (pts) with
Primary Advanced or Recurrent Endometrial Cancer
(pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
Who Received Follow-up Immunotherapy
731P
Impact of investigator-assessed response on overall survival
(OS) in patients (pts) with primary advanced or recurrent
endometrial cancer (pA/rEC) in the
ENGOT-EN6-NSGO/GOG3031/RUBY trial
734P
Durvalumab + carboplatin/paclitaxel (CP) followed by
durvalumab ± olaparib as a first-line treatment for
endometrial cancer (EC): progression-free survival (PFS) by
clinical factors in DUO-E
732P
Efficacy and safety of sacituzumab govitecan (SG) in
patients with advanced/metastatic endometrial cancer (EC):
updated results from TROPiCS-03
733P
Validation of circulating tumor DNA for prognostication and
monitoring in metastatic endometrial carcinoma: ancillary
results from the phase II randomized GINECO trial UTOLA
730P
Characterization of Tumor Response With Lenvatinib Plus
Pembrolizumab (LEN + Pembro) in the
ENGOT-en9/LEAP-001 Study
737P